Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

n Share (unaudited)
(Amounts in Millions, except per share figures)

Twelve months ended December 31, 2006

Purchase Acquisition- Other

As Accounting Related Specified As

Reported Adjustments Items Items Reconciled

Net sales $ 10,594 $ - $ - $ - $10,594

Cost of sales 3,697 - - (146)

3,551

Selling, general

and administrative 4,718 - - - 4,718

Research and

development 2,188 - - (15) 2,173

Acquired in-process

research and

development - - - - -

Other income, net (135) - - - (135)

Special and

acquisition

related charges 102 - - (102) -

Equity income (1,459) - - - (1,459)

Income before

income taxes 1,483 - - 263 1,746

Income tax expense 362 - - - 362

Net income before

cumulative effect

of a change in

accounting

principle $1,121 $ - $ - $263 $ 1,384

Cumulative effect

of a change in

accounting principle,

net of tax (22) - - 22 -

Net income $1,143 $ - $ - $241 $ 1,384

Preferred stock

dividends 86 - - - 86

Net income available

to common

shareholders $1,057 $ - $ - $241 $1,298

Diluted earnings<
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ... in Orthopedics, announced today the acquisition of Turner Medical, Inc ., thus ... surgical instruments to the Spine Industry. The acquisition of Turner Medical ideally supplements ...
(Date:7/1/2015)... PARK, N.C. and PARIS ... research firm AgBiome, and Genective, key developer of ... accelerate the discovery of new generations of insect ... for insect control to counter the realities of ... with Genective, aligning AgBiome,s unique insect control technology ...
(Date:7/1/2015)... ... , ... The next-generation sequencing (NGS) clinical market is poised for huge growth ... BCC Research reveals in its new report that the market drivers of this vibrant ... need for better diagnostics as part of a molecular diagnostics trend. , The global ...
(Date:7/1/2015)... PALO ALTO, Calif. , July 1, 2015 ... company focused on the development of groundbreaking drugs ... sclerosis (ALS), announced today that Robert G. ... Research Center at Sutter Health,s California Pacific Medical ... from The ALS Association for $1.5 million to ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced that it ... press release to be issued on Thursday,November 6, after ... company will,host a live webcast of its conference call ... November 7, at 8am EST/1pm GMT., The webcast ...
... quarter (26%) of primary care patients 40 years of age ... had airflow ... - Percentages were greater with increasing patient age and smoking ... findings from a cross-sectional study which showed,that 26 percent of ...
... Peptimmune, Inc., a privately,held biotechnology company, announced today that President ... Company,s current phase Ib clinical,trial for PI-2301 in multiple sclerosis ... Forum 2008. The presentation will take place on Wednesday, ... Pacific Room at the Palace Hotel in ...
Cached Biology Technology:deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results 2New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 2New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 3New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 4Peptimmune Presentations at Upcoming Events 2
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... Many insects living in northern climates don't die at the ... they use a number of specialized proteins to survive the ... insects will be back to bug us come spring. ... other insects suggests that they have an arsenal of protective ...
... $2 million grant from the National Institutes of Health ... physics-based virtual model that can simulate a patient's breathing ... 3-D models, adding the fourth dimension of time could ... for lung and liver cancers. , X. George ...
... natural "waste disposal" chemistry to mop up potentially toxic nitrogen ... cycle disorders --- most of them children – according to ... summarizing a quarter century of experience with the treatment. ... chemicals the body already makes to carry nitrogen for disposal ...
Cached Biology News:For many insects, winter survival is in the genes 2For many insects, winter survival is in the genes 3'Virtual Patient' to simulate real-time organ motions for radiation therapy 2An 'elegant' idea proves its worth 25 years later 2
... Vitro Osteogenesis Assay Kit contains all reagents ... mature osteoblastic lineage, as determined by staining ... all the necessary reagents and a protocol ... reader. This product is useful for studying ...
... BODIPY FL ATP-Gamma-S binds to ATP-binding ... the BODIPY FL fluorophore was linked ... addition to its potential use for ... thioether is an important new substrate ...
... workstation offers precise 96 and 384-well transfers ... 100ul and 200ul disposable tips, the 96 ... and precision across a volume range from ... two positions that enable indexing into 384 ...
... Tissue Arrays contain 60 rabbit tissue samples arrayed ... 4 unstained slides and 1 hematoxylin and eosin ... contains 15 different tissues from 4 rabbit organisms, ... slide. Each tissue sample (or core) is 1.5 ...
Biology Products: